XML 71 R35.htm IDEA: XBRL DOCUMENT
v3.20.1

Related Party Agreements (Details) |  |  |  |  |  |  |  |  | 1 Months Ended | 12 Months Ended
--- | --- | --- | --- | --- | --- | --- | --- | --- | --- | ---
Jan. 01, 2020 | Mar. 29, 2019 shares | Jan. 01, 2019 | Jan. 01, 2017 USD ($) shares | Jul. 31, 2016 | Jul. 27, 2016 | Jul. 26, 2016 USD ($) shares | Jul. 22, 2016 | May 31, 2019 USD ($) shares | Apr. 30, 2019 USD ($) shares | Mar. 29, 2019 USD ($) | Apr. 30, 2017 item | Jul. 31, 2016 shares | Dec. 31, 2019 USD ($) item shares | Dec. 31, 2018 USD ($) shares
Related Party Transaction [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Proceeds from loan |  |  |  |  |  |  |  |  |  |  | $ 15,000,000 |  |  |  |
Preferred stock voting rights multiplier |  |  |  |  |  |  | 1.1 |  |  |  |  |  |  |  |
Stock dividend (as a percent) | 2.50% |  | 2.00% |  | 2.50% |  |  |  |  |  |  |  |  |  |
Preferred Stock, Dividend Rate, Percentage | 2.50% |  | 2.00% |  | 2.50% |  |  |  |  |  |  |  |  |  |
At The Market Offering |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Related Party Transaction [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Proceeds from issuance of common shares |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 22,000,000 |
Public Offering |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Related Party Transaction [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Proceeds from issuance of common shares |  |  |  |  |  |  |  |  |  | $ 29,500,000 |  |  |  |  |
Fortress Biotech, Inc |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Related Party Transaction [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Share of equity or debt financing used to calculate equity fee or stock issuance to maintain parity (as a percent) |  |  |  |  |  |  |  | 2.50% |  |  |  |  |  |  |
Fortress Biotech, Inc | At The Market Offering |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Related Party Transaction [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Share of equity or debt financing used to calculate equity fee or stock issuance to maintain parity (as a percent) |  |  |  |  |  |  |  |  |  | 2.50% |  |  |  |  |
Issuance of common shares - Founders Agreement (in shares) | shares |  |  |  |  |  |  |  |  |  | 87,656 |  |  |  |  |
Expenses from related party transaction |  |  |  |  |  |  |  |  |  |  |  |  |  | 500,000 |
Proceeds from issuance of common shares |  |  |  |  |  |  |  |  |  | $ 22,500,000 |  |  |  |  |
Fortress Biotech, Inc | Issuances Related To Debt Financing |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Related Party Transaction [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Share of equity or debt financing used to calculate equity fee or stock issuance to maintain parity (as a percent) |  | 2.50% |  |  |  |  |  |  |  |  |  |  |  |  |
Issuance of common shares - Founders Agreement (in shares) | shares |  | 108,069 |  |  |  |  |  |  |  |  |  |  |  |  |
Expenses from related party transaction |  |  |  |  |  |  |  |  |  |  |  |  |  | 400,000 |
Fortress Biotech, Inc | Public Offering |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Related Party Transaction [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Share of equity or debt financing used to calculate equity fee or stock issuance to maintain parity (as a percent) |  |  |  |  |  |  |  |  | 2.50% |  |  |  |  |  |
Issuance of common shares - Founders Agreement (in shares) | shares |  |  |  |  |  |  |  |  | 197,656 |  |  |  |  |  |
Expenses from related party transaction |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 800,000 |
Proceeds from issuance of common shares |  |  |  |  |  |  |  |  | $ 31,600,000 |  |  |  |  |  |
Common Shares |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Related Party Transaction [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Issuance of common shares - Founders Agreement (in shares) | shares |  |  |  |  |  |  |  |  |  |  |  |  |  | 709,314 | 834,756
Number of shares converted | shares |  |  |  |  |  |  |  |  |  |  |  |  |  | 154,615 |
Class A Preferred Shares |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Related Party Transaction [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Issuance of common shares - Founders Agreement (in shares) | shares |  |  |  |  |  |  |  |  |  |  |  |  | 250,000 | 0 | 0
Number of shares converted | shares |  |  |  |  |  |  |  |  |  |  |  |  |  | 0 |
Shares issuable on conversion, per share converted | shares |  |  |  |  |  |  | 1 |  |  |  |  |  |  |  |
Class A Common Shares |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Related Party Transaction [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Issuance of common shares - Founders Agreement (in shares) | shares |  |  |  |  |  |  |  |  |  |  |  |  |  | 0 | 0
Number of shares converted | shares |  |  |  |  |  |  |  |  |  |  |  |  |  | (154,615) |
Maximum |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Related Party Transaction [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Expenses from related party transaction |  |  |  |  |  |  |  |  |  |  | $ 13,000,000 |  |  |  |
Fortress Biotech, Inc |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Related Party Transaction [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Expenses from related party transaction |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 500,000 | $ 500,000
Proceeds from loan |  |  |  |  |  |  | $ 2,000,000 |  |  |  |  |  |  |  |
Founders agreement term |  |  |  |  |  |  | 15 years |  |  |  |  |  |  |  |
Agreement renewal term |  |  |  |  |  | 1 year | 1 year |  |  |  |  |  |  |  |
Paid in kind dividend, period prior to payment date for measuring ownership |  |  |  |  |  |  | 1 day |  |  |  |  |  |  |  |
Equity fee, period for payment after financing |  |  |  |  |  |  |  |  |  |  |  |  |  | 5 days |
Equity fee payable in shares (as a percent) |  |  |  |  |  |  |  |  |  |  |  |  |  | 2.50% |
Cash fee (as a percent) |  |  |  |  |  |  |  |  |  |  |  |  |  | 4.50% |
Cash fee, period for payment |  |  |  |  |  |  |  |  |  |  |  |  |  | 90 days |
Change in control fee, multiplier | item |  |  |  |  |  |  |  |  |  |  |  |  |  | 5 |
Change in control fee, measurement period |  |  |  |  |  |  |  |  |  |  |  |  |  | 12 months |
Change in control fee, specified rate component |  |  |  |  |  |  |  |  |  |  |  |  |  | 4.50% |
Annual consulting fee |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 500,000 |
Consulting fee when net assets exceed threshold |  |  |  |  |  |  |  |  |  |  |  |  |  | 1,000,000 |
Net assets threshold |  |  |  |  |  |  |  |  |  |  |  |  |  | 100,000,000 |
Option award, number of related party recipients | item |  |  |  |  |  |  |  |  |  |  |  | 2 |  |  |
Fortress Biotech, Inc | Common Class B |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Related Party Transaction [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of shares converted | shares |  |  |  |  |  |  | 7,250,000 |  |  |  |  |  |  |  |
Fortress Biotech, Inc | Common Shares |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Related Party Transaction [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of shares issued in conversion | shares |  |  |  |  |  |  | 7,000,000 |  |  |  |  |  |  |  |
Fortress Biotech, Inc | Class A Preferred Shares |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Related Party Transaction [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of shares issued in conversion | shares |  |  |  |  |  |  | 250,000 |  |  |  |  |  |  |  |
Director [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Related Party Transaction [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Expenses from related party transaction |  |  |  |  |  |  |  |  |  |  |  |  |  | 102,000 | 84,000
Annual consulting fee |  |  |  |  |  |  |  |  |  |  |  |  |  | 50,000 |
Value of shares granted as compensation |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 52,000 | $ 34,000
Number of shares granted as compensation | shares |  |  |  |  |  |  |  |  |  |  |  |  |  | 34,000 | 20,000
Director [Member] | Maximum |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Related Party Transaction [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Value of shares granted as compensation |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 50,000 |
Number of shares granted as compensation | shares |  |  |  |  |  |  |  |  |  |  |  |  |  | 10,000 |
Board of Directors Chairman [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Related Party Transaction [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Expenses from related party transaction |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 105,000 | $ 84,000
Annual consulting fee |  |  |  | $ 60,000 |  |  |  |  |  |  |  |  |  |  |
Value of shares granted as compensation |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 45,000 | $ 34,000
Number of shares granted as compensation | shares |  |  |  |  |  |  |  |  |  |  |  |  |  | 34,000 | 20,000
Board of Directors Chairman [Member] | Maximum |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Related Party Transaction [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Value of shares granted as compensation |  |  |  | $ 50,000 |  |  |  |  |  |  |  |  |  |  |
Number of shares granted as compensation | shares |  |  |  | 10,000 |  |  |  |  |  |  |  |  |  |  |

X
- Definition The period of time for which the agreement may be renewed. + References No definition available. + Details
Name: | mbio_AgreementRenewalTerm
Namespace Prefix: | mbio_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition This element represents the amount of annual consulting fees. + References No definition available. + Details
Name: | mbio_AnnualConsultingFees
Namespace Prefix: | mbio_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The cash fee payable as a percentage of annual net sales. + References No definition available. + Details
Name: | mbio_CashFeeAsPercentageOfAnnualNetSales
Namespace Prefix: | mbio_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition The number of days after the end of the calendar year allowed for payment of the cash fee. + References No definition available. + Details
Name: | mbio_CashFeePaymentPeriod
Namespace Prefix: | mbio_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition The period of time for measurement of net sales used as a component in the calculation of the change in control fee. + References No definition available. + Details
Name: | mbio_ChangeInControlFeeMeasurementPeriodForNetSales
Namespace Prefix: | mbio_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition The multiple applied to the product of sales and the specified rate, to determine the change in control fee. + References No definition available. + Details
Name: | mbio_ChangeInControlFeeMultipleAppliedToProductOfSalesAndSpecifiedRate
Namespace Prefix: | mbio_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition The specified rate component in the calculation of the change in control fee. + References No definition available. + Details
Name: | mbio_ChangeInControlFeeSpecifiedRateComponent
Namespace Prefix: | mbio_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the percentage of diluted outstanding equity paid as equity fee or used to calculate stock issuance to maintain parity. + References No definition available. + Details
Name: | mbio_DilutedOutstandingEquityPercentage
Namespace Prefix: | mbio_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition The number of shares granted, or to be granted, as a component of director compensation. + References No definition available. + Details
Name: | mbio_DirectorCompensationNumberOfSharesGranted
Namespace Prefix: | mbio_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition The market value of shares granted, or to be granted, as a component of director compensation. + References No definition available. + Details
Name: | mbio_DirectorCompensationValueOfSharesGranted
Namespace Prefix: | mbio_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The number of days after closing of equity or debt financing allowed for payment of the equity fee. + References No definition available. + Details
Name: | mbio_EquityFeePaymentPeriod
Namespace Prefix: | mbio_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition The percentage of equity or debt financing payable as an equity fee. + References No definition available. + Details
Name: | mbio_EquityFeePercentageOfFinancing
Namespace Prefix: | mbio_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition This element represents the amount of net assets in excess of liabilities. + References No definition available. + Details
Name: | mbio_ExcessInNetAssetsValue
Namespace Prefix: | mbio_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition This element represents the agreement term with the founders. + References No definition available. + Details
Name: | mbio_FoundersAgreementTerm
Namespace Prefix: | mbio_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition This element represents the increase in the amount of annual consulting fees. + References No definition available. + Details
Name: | mbio_IncreaseInAnnualConsultingFees
Namespace Prefix: | mbio_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The number of employees that received option awards. + References No definition available. + Details
Name: | mbio_NumberOfEmployeesReceivingOptionAward
Namespace Prefix: | mbio_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition The number of days prior to the dividend payment date that the outstanding capitalization is to be measured. + References No definition available. + Details
Name: | mbio_OutstandingCapitalizationNumberOfDaysPriorToPaymentForMeasurement
Namespace Prefix: | mbio_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition The multiplier applied to shares of stock to determine the voting rights per share. + References No definition available. + Details
Name: | mbio_PreferredStockVotingRightsMultiplier
Namespace Prefix: | mbio_
Data Type: | xbrli:decimalItemType
Balance Type: | na
Period Type: | duration

X
- Definition The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4313-108586 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4304-108586 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4332-108586 + Details
Name: | us-gaap_ConversionOfStockSharesConverted1
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4332-108586 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4313-108586 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4304-108586 + Details
Name: | us-gaap_ConversionOfStockSharesIssued1
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of shares issued for each share of convertible preferred stock that is converted. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(27)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 6 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644 + Details
Name: | us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition The percentage rate used to calculate dividend payments on preferred stock. + References No definition available. + Details
Name: | us-gaap_PreferredStockDividendRatePercentage
Namespace Prefix: | us-gaap_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585 + Details
Name: | us-gaap_ProceedsFromIssuanceOrSaleOfEquity
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585 + Details
Name: | us-gaap_ProceedsFromRelatedPartyDebt
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 850 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864 + Details
Name: | us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_RelatedPartyTransactionLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders. + References No definition available. + Details
Name: | us-gaap_StockIssuedDuringPeriodSharesIssuedForServices
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_SubsidiarySaleOfStockAxis=mbio_AtMarketOfferingMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsidiarySaleOfStockAxis=mbio_PublicOfferingMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=mbio_FortressBiotechIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsidiarySaleOfStockAxis=mbio_IssuancesRelatedToDebtFinancingMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementClassOfStockAxis=mbio_CommonUnspecifiedClassMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mbio_FortressBiotechIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_DirectorMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_BoardOfDirectorsChairmanMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |